THE LACK OF CONSISTENT DIASPIRIN CROSS-LINKED HEMOGLOBIN INFUSION BLOOD PRESSURE EFFECTS IN THE US AND EU TRAUMATIC HEMORRHAGIC SHOCK CLINICAL TRIALS
Authors:
- Edward P. SloanESEdward P. Sloan
- Nora B. PhilbinNPNora B. Philbin
- Max D. KoenigsbergMKMax D. Koenigsberg
- Weihua GaoWGWeihua Gao
- 1 February 2010
- journal article
- research article
- Published by Wolters Kluwer Health in Shock
- Vol. 33 (2) , 123-133
Abstract
Hemoglobin solutions have demonstrated a pressor effect that could adversely affect hemorrhagic shock patient resuscitation through accelerated hemorrhage, diminished perfusion, or inadequate resuscitation. Data from two parallel, multicenter traumatic hemorrhagic shock clinical trials in 17 US emergency departments and in 27 EU prehospital systems using diaspirin cross-linked hemoglobin (DCLHb), a hemoglobin-based resuscitation fluid. In the 219 patients, patients were 37 years old, 64% sustained blunt injury, 48% received DCLHb, and 36% expired. Although mean systolic blood pressure (SBP) and diastolic blood pressure values differed at 2 of the 10 measured time points, blood pressure (BP) curve analysis showed no SBP, diastolic blood pressure, or MAP differences based on treatment. Although SBP values 160 and 120 mmHg or greater were 2.2× and 2.6× more frequently noted in survivors, they were not more common with DCLHb use or in DCLHb patients who expired in US study nonsurvivors or in any EU study patients. Systolic blood pressure values 160 and 120 mmHg or greater were 2.8× and 1.3× more frequently noted in DCLHb survivors as compared with normal saline survivors. Only 3% of the BP variation noted could be attributed to DCLHb use, and as expected, injury severity and baseline physiologic status were stronger predictors. In the United States alone, treatment group was not correlated by regression with BP at any time point. Neither mean BP readings nor elevated BP readings were correlated with DCLHb treatment of traumatic hemorrhagic shock patients. As such, no clinically demonstrable DCLHb pressor effect could be directly related to the adverse mortality outcome observed in the US study.Keywords
This publication has 60 references indexed in Scilit:
- Human Polymerized Hemoglobin for the Treatment of Hemorrhagic Shock when Blood Is Unavailable: The USA Multicenter TrialJournal of the American College of Surgeons, 2009
- Hemoglobin-based oxygen carrying compound-201 as salvage therapy for severe neuro- and polytrauma (Injury Severity Score = 27–41)*Critical Care Medicine, 2008
- A randomized, single‐blind, increasing dose safety trial of an oxygen‐carrying plasma expander (Hemospan®) administered to orthopaedic surgery patients with spinal anaesthesiaTransfusion Medicine, 2008
- Early Hyperglycemia Predicts Multiple Organ Failure and Mortality but Not InfectionJournal of Trauma: Injury, Infection & Critical Care, 2007
- First-generation blood substitutes: what have we learned? Biochemical and physiological perspectivesExpert Opinion on Biological Therapy, 2007
- Systemic Responses to Hemodilution After Transfusion with Stored Blood and with a Hemoglobin-Based Oxygen CarrierAnesthesia & Analgesia, 2005
- Hemoglobin-Based Oxygen Carrier Distribution Inside Vascular Wall and Arterial Pressure Evolution: Is There a Relationship?European Surgical Research, 2005
- Either sufentanil or fentanyl, in addition to intrathecal bupivacaine, provide satisfactory early labour analgesiaCanadian Journal of Anesthesia/Journal canadien d'anesthésie, 2001
- Site-specific modifications and toxicity of blood substitutesAdvanced Drug Delivery Reviews, 2000
- Phase I study of the safety and pharmacologic effects of diaspirin cross-linked hemoglobin solutionCritical Care Medicine, 1996